Market Place
Sourcing Support
Lineage Announces Formation Of Scientific Advisory Board
13 Apr 2026 //
PHARMIWEB
Lineage Launches Cell Therapy for Corneal Endothelial Disease
24 Mar 2026 //
PHARMIWEB
Lineage Receives Hypoimmune Gene-Edited Cell Line From Factor Bio
06 Jan 2026 //
BUSINESSWIRE
Lineage Cell Therapeutics Issues Letter To Stockholders
05 Jan 2026 //
BUSINESSWIRE
Lineage Cell Therapeutics Unveils Q3 2025 Financials
06 Nov 2025 //
BUSINESSWIRE
Lineage Cell Therapeutics To Release Q3 2025 Financials Result
30 Oct 2025 //
BUSINESSWIRE
Lineage Initiates Cell Transplant Program for Type 1 Diabetes
08 Sep 2025 //
PHARMAWEB
Lineage Cell Therapeutics to Present at Investor Conferences
02 Sep 2025 //
PHARMAWEB
Lineage Tunes up Hearing Loss Transplant with $12 M Research Pact
26 Aug 2025 //
FIERCE BIOTECH
Lineage Cell Therapeutics Q2 2025 Financial Results and Update
12 Aug 2025 //
BUSINESSWIRE
OpRegen® (RG6501) 36-Month Visual Acuity Results at Summit 2025
23 Jun 2025 //
BUSINESSWIRE
Lineage Gives Update at 3rd Spinal Cord Injury Symposium
05 Jun 2025 //
BUSINESSWIRE
Lineage Cell Therapeutics Reports Q1 2025 Results & Update
13 May 2025 //
BUSINESSWIRE
RG6501 36-Month Results to Be Shared at CT Summit
12 May 2025 //
BUSINESSWIRE
Lineage Cell Therapeutics to Report Q1 2025 Results on May 13
01 May 2025 //
BUSINESSWIRE
Lineage Cell Therapeutics & Christopher & Dana Reeve Foundation
22 Apr 2025 //
BUSINESSWIRE
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by AAO
21 Apr 2025 //
BUSINESSWIRE
Lineage Cell Therapeutics Reports Q4 and Full Year 2024 Financial
10 Mar 2025 //
BUSINESSWIRE
Lineage To Report Q4, FY24 Results, Business Update On March 10
05 Mar 2025 //
BUSINESSWIRE
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
11 Feb 2025 //
BUSINESSWIRE
Lineage Cell Therapeutics to Present at Oppenheimer Conference
04 Feb 2025 //
BUSINESSWIRE
Lineage Cell Therapeutics Issues Letter to Stockholders
06 Jan 2025 //
BUSINESSWIRE
Lineage Cell Therapeutics Closes $66M Registered Offering
21 Nov 2024 //
BUSINESSWIRE
Lineage Cell Therapeutics Announces $66M Direct Offering
20 Nov 2024 //
BUSINESSWIRE
Lineage Cell Therapeutics Reports Q3 2024 Financial Results
14 Nov 2024 //
BUSINESSWIRE
Lineage Cell Therapeutics to Report Q3 2024 Results on Nov 14
07 Nov 2024 //
BUSINESSWIRE
OpRegen® Results To Be Featured At ISSCR 2024 Symposium
25 Sep 2024 //
BUSINESSWIRE
Lineage Cell To Present At H.C. Wainwright Ophthalmology Conference
13 Aug 2024 //
BUSINESSWIRE
Lineage Cell Therapeutics Reports Q2 2024 Results And Business Update
08 Aug 2024 //
BUSINESSWIRE
OpRegen® Phase 1/2a study shows promising 24-month visual results
06 May 2024 //
BUSINESSWIRE
Lineage to Present at Baird 2023 Global & H.C. Wainwright & Co. 25th Conference
29 Aug 2023 //
BUSINESSWIRE
Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index
22 May 2023 //
BUSINESSWIRE
Lineage Cell to Report 1Q 2023 FYR & Business Update on May 11, 2023
04 May 2023 //
BUSINESSWIRE
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen
26 Apr 2023 //
BUSINESSWIRE
RG6501 Phase 1/2a Results to Be Presented at 2023 Retinal Cell Summit
20 Mar 2023 //
BUSINESSWIRE
